既往腹主动脉瘤修复术后开窗分支腔内修复术的结局
30天死亡率为1.1%,早期临床成功率为94.6%,中位随访36个月生存率可接受,但使用cuff与远端再干预需求增加相关。
要点
- 既往腹主动脉瘤修复后开窗分支腔内修复术围手术期死亡率和并发症率低。
- 中期生存率和免于再干预率可接受。
- 使用cuff较relining与更高的远端再干预需求相关。
核心结论
- 既往开放或腔内腹主动脉瘤修复后行开窗分支腔内修复术围手术期死亡率和并发症率低,中期生存率和免于再干预率可接受。
- 使用开窗分支腔内修复术cuff较relining原始修复与更高的远端再干预需求相关。
研究设计与样本
- 中位年龄75岁(IQR 71-80岁),中位直径73 mm(IQR 64-89 mm),82例择期,10例急性。
- 既往开放修复47例,既往腔内修复45例。
主要发现
- 30天死亡率为1.1%,1例(1.1%)需永久透析,1例(1.1%)出现暂时性脊髓缺血。
- 早期主要临床成功率为94.6%,主要技术成功率为95.6%。
- 中位随访36个月(IQR 23-64个月),1年、2年、3年总体生存率分别为86%±4%、85%±4%、70%±5%。
临床怎么用
- 对于既往腹主动脉瘤修复后近端主动脉病变患者,开窗分支腔内修复术是一种围手术期风险较低的选项。
- 选择cuff处理时需警惕远端再干预风险较高。
局限性
- 单中心回顾性研究。
- 样本量有限。
- 部分亚组分析未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report the outcome of fenestrated and branch endovascular aortic repair (FEVAR-BEVAR) for asymptomatic and acute symptomatic proximal aortic pathology in patients with prior open (OSR) or endovascular (EVAR) abdominal aortic aneurysm (AAA) repair. METHODS: This was a single centre retrospective study of consecutive patients with non-ruptured (asymptomatic and acute symptomatic) proximal aortic pathology after prior OSR or EVAR treated between December 2007 and February 2020. The primary endpoint was 30 day/in hospital mortality. Secondary endpoints were technical success, primary clinical success, and Kaplan-Meier estimates of medium term survival and freedom from re-intervention. Data are presented as median (interquartile range [IQR]). The effect of covariates on medium term survival was estimated using multivariable (Cox proportional hazards model) analysis. A p value < .05 was considered to be statistically significant. RESULTS: Ninety-two patients (83 men; median age 75 years [IQR 71 - 80 years]; median diameter 73 mm [IQR 64 - 89 mm]; 82 elective, 10 acute) underwent FEVAR-BEVAR after prior OSR (n = 47) or EVAR (n = 45). Indications for intervention were aneurysmal degeneration with or without type 1a endoleak (n = 57; four juxtarenal [JR] AAA, 21 extent II/III, 32 extent IV thoraco-abdominal aortic aneurysms); type 1a endoleak alone (n = 27) and to create a more durable repair after acute infrarenal EVAR (n = 8; JRAAA). In total, 348 renovisceral vessels were targeted for preservation and 324 were stent grafted. Twenty-four unstented vessels comprised one bypass, 11 scallops and six fenestrations intentionally not stent grafted, two vessels occluded before graft implantation, and four vessels occluded intra-operatively. Primary technical success was 95.6%. The thirty day mortality rate was 1.1% and one patient each (1.1%) required permanent dialysis or developed temporary spinal cord ischaemia. Early primary clinical success was 94.6%. Median follow up was 36 months (IQR 23 - 64 months). Estimated overall survival (± standard error) at one, two, and three years was 86% ± 4%, 85% ± 4%, and 70% ± 5%, respectively. Multivariable analysis did not demonstrate any independent predictors of survival. Four target vessels occluded during follow up. Nineteen patients underwent 28 late re-interventions, with almost half performed for issues arising distal to the FEVAR-BEVAR. Patients treated with a cuff were statistically significantly more likely to require distal re-intervention compared with those treated by relining (9/49 vs. 1/43, p = .018 [odds ratio 9.3, 95% confidence interval 1.2 - 423]). In patients with prior EVAR alone, this did not reach statistical significance (cuff 7/25 vs. relining 1/20, p = .059 [odds ratio 7.1, 95% confidence interval 0.8 - 350]). Estimated freedom from re-intervention at one, two, and three years was 88% ± 3%, 81% ± 4%, and 81% ± 4%, respectively. CONCLUSION: FEVAR-BEVAR after prior OSR or EVAR is associated with low peri-operative morbidity and mortality, and acceptable medium term survival and freedom from re-intervention. Treatment with a FEVAR-BEVAR cuff is associated with a higher requirement for distal re-intervention than relining of the original repair.
引用
- Juszczak M, Vezzosi M, Nasr H, et al. Fenestrated-Branch Endovascular Repair After Prior Abdominal Aortic Aneurysm Repair. Eur J Vasc Endovasc Surg. 2021. PMID: 34474963. doi:10.1016/j.ejvs.2021.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。